Gilenya (jill-LEN-nee-ya, fingolimod) is the first ORAL drug to reduce relapses in relapsing multiple sclerosis (MS)
Please see the May 2012 FDA safety communication concerning Gilenya
Gilenya (jill-LEN-nee-ya, fingolimod) is the first ORAL drug to reduce relapses in relapsing multiple sclerosis (MS).It's a new immune modulator that prevents some white blood cells from migrating to the CNS and damaging it.
Gilenya is approved for first-line use...but don't expect it to replace beta-interferons (Avonex, etc) or Copaxone (glatiramer). These drugs have a longer safety record and they're less expensive.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote